Corbus Pharmaceuticals Holdings (Corbus Pharmaceuticals Holdings) Margin of Safety % (DCF Dividends Based) : N/A (As of Apr. 28, 2024)

View and export this data going back to 2014. Start your Free Trial

What is Corbus Pharmaceuticals Holdings Margin of Safety % (DCF Dividends Based)?

Margin of Safety % (DCF Dividends Based) = (Intrinsic Value: DCF (Dividends Based) - Current Price) / Intrinsic Value: DCF (Dividends Based).

Note: Discounted Dividend model is only suitable for companies who have a consistant distribution history with more than 5 years. If the company's dividends does not remain steady over a long period, results may not be accurate due to the low consistency. The model is also only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, the data will not be stored into our database.

Corbus Pharmaceuticals Holdings's Predictability Rank is 1-Star. Thus, the DCF related results in the screener and portfolio will appear as zero and Margin of Safety % (DCF Dividends Based) is not calculated.

Competitive Comparison of Corbus Pharmaceuticals Holdings's Margin of Safety % (DCF Dividends Based)

For the Biotechnology subindustry, Corbus Pharmaceuticals Holdings's Margin of Safety % (DCF Dividends Based), along with its competitors' market caps and Margin of Safety % (DCF Dividends Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Corbus Pharmaceuticals Holdings's Margin of Safety % (DCF Dividends Based) Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Corbus Pharmaceuticals Holdings's Margin of Safety % (DCF Dividends Based) distribution charts can be found below:

* The bar in red indicates where Corbus Pharmaceuticals Holdings's Margin of Safety % (DCF Dividends Based) falls into.

Corbus Pharmaceuticals Holdings Margin of Safety % (DCF Dividends Based) Related Terms

Thank you for viewing the detailed overview of Corbus Pharmaceuticals Holdings's Margin of Safety % (DCF Dividends Based) provided by GuruFocus.com. Please click on the following links to see related term pages.

Corbus Pharmaceuticals Holdings (Corbus Pharmaceuticals Holdings) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Corbus Pharmaceuticals Holdings Inc (NAS:CRBP) » Definitions » Margin of Safety % (DCF Dividends Based)

Comparable Companies

Traded in Other Exchanges

3371:Germany

Address

500 River Ridge Drive, Norwood, MA, USA, 02062

Website

https://www.corbuspharma.com

Corbus Pharmaceuticals Holdings Inc is a clinical-stage pharmaceutical company focused on the development and commercialization of novel therapeutics for endocannabinoid or immune systems. The company's lead product candidate, lenabasum, is a novel, synthetic oral endocannabinoid-mimetic drug designed to resolve chronic inflammation and fibrotic processes. Lenabasum is currently being evaluated in systemic sclerosis, cystic fibrosis, dermatomyositis, and systemic lupus erythematosus. Corbus' internal development pipeline includes CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload and CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells.

Executives

Yong Ben	director	500 RIVER RIDGE DRIVE, NORWOOD MA 02062
Anne Altmeyer	director	500 RIVER RIDGE DRIVE, NORWOOD MA 02062
Yuval Cohen	director, officer: Chief Executive Officer	C/O CORBUS PHARMACEUTICALS HOLDINGS, INC, 100 RIVER RIDGE DRIVE, NORWOOD MA 02062
Craig Stuart Millian	officer: Chief Commercial Officer	C/O CORBUS PHARMACEUTICALS HOLDINGS, INC, 100 RIVER RIDGE DRIVE, NORWOOD MA 02062
Sean F. Moran	officer: Chief Financial Officer	10220-L OLD COLUMBIA ROAD, COLUMBIA MD 21046
Rachael Louise Brake	officer: Chief Scientific Officer	21 MANCHESTER PLACE, NATICK MA 01760
George Golumbeski	director	C/O CELGENE CORP., 86 MORRIS AVENUE, SUMMIT NJ 07901
Peter Salzmann	director	320 W 37TH STREET, 3RD FLOOR, NEW YORK NY 10016
Barbara White	officer: Chief Medical Officer	C/O CORBUS PHARMACEUTICALS HOLDINGS, INC, 100 RIVER RIDGE DRIVE, NORWOOD MA 02062
Robert Paul Discordia	officer: Chief Operating Officer	C/O CORBUS PHARMACEUTICALS HOLDINGS, INC, 500 RIVER RIDGE DRIVE, NORWOOD MA 02062
Rachelle Suzanne Jacques	director	C/O CORBUS PHARMACEUTICALS HOLDINGS, INC, 100 RIVER RIDGE DRIVE, NORWOOD MA 02062
David P Hochman	director	15 WESTON HILL RD., RIVERSIDE CT 06878
John Kenneth Jenkins	director	C/O CORBUS PHARMACEUTICALS HOLDINGS, INC, 100 RIVER RIDGE DRIVE, NORWOOD MA 02062
Paris Panayiotopoulos	director	ARIAD PHARMACEUTICALS, INC., 26 LANDSDOWNE STREET, CAMBRIDGE MA 02139
Alan F Holmer	director	C/O CORBUS PHARMACEUTICALS HOLDINGS, INC, 100 RIVER RIDGE DRIVE, NORWOOD MA 02062